Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:37:49.381Z.
Calculation as of: 2026-10-06T19:37:49.381Z.
Quote observation: 2026-10-06T19:35:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.54B | N/A | N/A | N/A | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.61B | 0.71 | 0.70 | 0.72 | 0.78 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.61B | 21.82 | 21.26 | 66.13 | 66.13 |
| Insulet Corp. (PODD)vs › | $9.30B | 3.05 | 5.81 | 7.90 | 10.90 |
| Bruker Corporation (BRKR)vs › | $9.20B | 2.63 | 2.11 | 2.59 | 3.21 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 3.83 | 3.24 | 3.25 | 4.05 |
| Repligen Corporation (RGEN)vs › | $9.91B | 12.62 | 11.23 | 12.59 | 13.74 |
| The Ensign Group, Inc. (ENSG)vs › | $10.02B | 1.83 | 2.12 | 1.99 | 1.88 |
| Bruker Corporation (BRKRP)vs › | $8.95B | 2.56 | 16.13 | 15.78 | 15.78 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.96B | 11.54 | 14.70 | 14.34 | 37.05 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
